Zogenix Announces Ruling Preventing the Implementation of Massachusetts Governor's Order that Prevented Access to Zohydro™ ER

Zogenix, Inc. (ZGNX), a pharmaceutical company developing and commercializing products for the treatment of pain-related and central nervous system (CNS) disorders, today announced that the U.S. District Court in Massachusetts entered an order, preventing the implementation of the Commonwealth's ban of Zohydro™ ER on Constitutional grounds.  This order will become effective on April 22, 2014.

The court decision today supports the importance of upholding the Constitutional principle at the heart of this case. The United States Food and Drug Administration (FDA) approved Zohydro™ ER (hydrocodone bitartrate) Extended-Release Capsules, CII, for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate.

Apricus Biosciences' Partner in the United Kingdom Accepts First Shipment of Vitaros(R)

Takeda UK to be the First to Launch Vitaros^(R) in Europe

Apricus Anticipates Follow-On Vitaros Product Shipments and Launches Throughout 2014

SAN DIEGO, April 16, 2014 - Apricus Biosciences, Inc. (APRI), a pharmaceutical company focusing on the development and commercialization of novel therapeutics for men's and women's health, today announced that Takeda Pharmaceuticals International GmbH, the Company's partner in the United Kingdom, has accepted the first shipment of Vitaros^(R), Apricus' novel topical on-demand treatment for erectile dysfunction ("ED").